These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 15955377

  • 1. Influence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patients.
    Mayorov AY, Naumenkova IV, Antsiferov MB, Dedov II.
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S54-9. PubMed ID: 15955377
    [Abstract] [Full Text] [Related]

  • 2. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
    Rowe R, Cowx M, Poole C, McEwan P, Morgan C, Walker M.
    Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
    [Abstract] [Full Text] [Related]

  • 3. Insulin sensitivity in Type 1 diabetic children and adolescents.
    Szadkowska A, Pietrzak I, Mianowska B, Bodalska-Lipińska J, Keenan HA, Toporowska-Kowalska E, Młynarski W, Bodalski J.
    Diabet Med; 2008 Mar; 25(3):282-8. PubMed ID: 18279410
    [Abstract] [Full Text] [Related]

  • 4. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo?
    Burén J, Lindmark S, Renström F, Eriksson JW.
    Metabolism; 2003 Feb; 52(2):239-45. PubMed ID: 12601640
    [Abstract] [Full Text] [Related]

  • 5. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects.
    Heliövaara MK, Teppo AM, Karonen SL, Tuominen JA, Ebeling P.
    Diabetes Obes Metab; 2005 Nov; 7(6):729-36. PubMed ID: 16219017
    [Abstract] [Full Text] [Related]

  • 6. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.
    J Diabetes Complications; 2007 Nov; 21(1):20-7. PubMed ID: 17189870
    [Abstract] [Full Text] [Related]

  • 7. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [Abstract] [Full Text] [Related]

  • 8. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 9. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 10. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 11. Oral magnesium supplementation in insulin-requiring Type 2 diabetic patients.
    de Valk HW, Verkaaik R, van Rijn HJ, Geerdink RA, Struyvenberg A.
    Diabet Med; 1998 Jun; 15(6):503-7. PubMed ID: 9632126
    [Abstract] [Full Text] [Related]

  • 12. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study.
    Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI.
    Diabet Med; 2005 Mar; 22(3):316-22. PubMed ID: 15717881
    [Abstract] [Full Text] [Related]

  • 13. Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance.
    Annuzzi G, Giacco R, Patti L, Di Marino L, De Natale C, Costabile G, Marra M, Santangelo C, Masella R, Rivellese AA.
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):531-8. PubMed ID: 18321693
    [Abstract] [Full Text] [Related]

  • 14. [Cardiovascular risk factors and treatment with insulin in type II diabetic patients in whom oral hypoglycemic drugs have failed].
    Calle Pascual AL, Calle Fernández JR.
    Med Clin (Barc); 1993 Jun 26; 101(5):165-7. PubMed ID: 8332008
    [Abstract] [Full Text] [Related]

  • 15. [The effect of a short-term reducing diet on the effect of insulin in type 2 diabetes mellitus].
    Sindelka G, Skrha J, Hilgertová J, Justová V.
    Cas Lek Cesk; 1997 Sep 10; 136(17):530-2. PubMed ID: 9441013
    [Abstract] [Full Text] [Related]

  • 16. Impact of obesity on insulin action in NIDDM.
    Campbell PJ, Carlson MG.
    Diabetes; 1993 Mar 10; 42(3):405-10. PubMed ID: 8432411
    [Abstract] [Full Text] [Related]

  • 17. Blood-glucose self-monitoring in insulin treated type 2 diabetes mellitus a cross-sectional study with an intervention group.
    Schiel R, Müller UA, Rauchfub J, Sprott H, Müller R.
    Diabetes Metab; 1999 Sep 10; 25(4):334-40. PubMed ID: 10566123
    [Abstract] [Full Text] [Related]

  • 18. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
    Hausmann M, Dellweg S, Osborn C, Heinemann L, Buchwald A, Rosskamp R, Genova P, Heise T.
    Diabetes Obes Metab; 2006 Sep 10; 8(5):574-80. PubMed ID: 16918593
    [Abstract] [Full Text] [Related]

  • 19. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov 10; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 20. Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range.
    Jani R, Molina M, Matsuda M, Balas B, Chavez A, DeFronzo RA, Abdul-Ghani M.
    Diabetes Care; 2008 Feb 10; 31(2):311-5. PubMed ID: 18000182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.